VENUSREMVENUSREM Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market CapN/A
Primary DriverGovernance
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
6 / 100
-5 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in governance. This indicates that forensic pressure is currently receding. Risk levels are improving.

15.2th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹1,411.3▲5%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Stability Adjustment
+6.0 pts
Final Composite Risk6 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 7 → 6 over 12 quarters.

Expected Direction
🟢 Improving
Primary Deterioration Drivers
  • Industrial Margin Stress
  • Working Capital Expansion
  • Profit Collapse
What to Watch Next Quarter
  • Operating profit margins
  • Working capital efficiency

Active Risk Objects (3)

CriticalHigh
Profit Collapse
📊 Earnings QualityQuarterlyActive for 2 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ2 FY2025
VENUSREM: Net Profit collapsed by 64.6% from FY2024 Q2 to FY2025 Q2.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 4 Years
More Detail
Impact Weight12/15
MomentumPersistent
Last SignalQ2 FY2026
VENUSREM: Raw material costs consumed an additional 3.1% of revenue YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 3 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ2 FY2026
Working capital expansion detected: Receivable days increased by 30.5%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)4.647.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+60.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,411.3(+5%)
1M Divergence+43.62%
1 Week+21.55%
1 Month+45.89%
6 Months+84.69%
1 Year+207.21%
2 Year+337.07%
3 Year+485.12%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.

VENUSREM • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.98%
Trend QualityStrong
Phase Progression
Phase Progression Score100%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing98%
CoinTree Momentum
Composite Z-Score+3.3852σ
Strong positive momentum leadership
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#27 of 2716
Top 0.99% in momentum strength
Timeframe Sparklines
1W+21.6%
1M+45.9%
6M+84.7%
Weinstein Indicators
150 DMA₹795.59
200 DMA₹712.34
150 DMA Slope+11.3604%Rising
Relative Strength+90.71%Leading
Relative Turnover (RTR)1.5159
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

VENUSREMVENUSREM
6 Risk
Sector %ile15th
Delta-5
Active Flags3
Accel+0
Governance

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Industrial Margin Stress

2026

Working Capital Expansion

2026

Industrial Margin Stress

2025

Industrial Margin Stress

2025

Working Capital Expansion

2024

Industrial Margin Stress

2024

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY2026782103156-
FY202566945862
FY2024613283741
FY2023566273742